thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Its vessels serve routes to and from Bacolod, Batangas, Butuan, Cagayan de Oro, Caticlan, Cebu, Coron, Davao, Dipolog, Dumaguete, General Santos, Iloilo, Manila, Odiongan, Ozamiz, Puerto Princesa, Roxas, Siargao, Tagbilaran, and Zamboanga.
October 28, 2008 United Kingdom 500,000 mortgage holders are left in negative equity after house prices dropped 15% since the previous summer, with another 700,000 mortgage holders facing the same risk if prices continue to fall.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million. In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million. In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M. In April 2022, the company announced it would acquire Explora BioLabs. In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Sources: en.wikipedia.org
Scottish scientist James W. Black developed propranolol in the 1960s. It was the first beta blocker effectively used in the treatment of coronary artery disease and hypertension. Black received the Nobel Prize in Physiology or Medicine in 1988 for this discovery. Propranolol is on the WHO Model list of essential medicines. Newer, more cardio-selective beta blockers (such as bisoprolol, nebivolol, carvedilol, or metoprolol) are used preferentially in the treatment of hypertension.
Over the next three decades, 1895–1925, as food canning was approaching a billion-dollar-a-year industry, botulism was becoming a public health hazard. Karl Friedrich Meyer, a Swiss-American veterinary scientist, created a center at the Hooper Foundation in San Francisco, where he developed techniques for growing the organism and extracting the toxin, and conversely, for preventing organism growth and toxin production, and inactivating the toxin by heating. The California canning industry was thereby preserved.
On 16 May 2023, three weeks after Tangaraju was put to death, 36-year-old Muhammad Faizal Mohd Shariff, a Singaporean who was found guilty in 2019 of trafficking 1.5 kg of marijuana was reported to have lost his final appeal to commute his sentence. A day after losing his appeal, Muhammad Faizal was hanged at dawn on 17 May 2023, with the authorities confirming his execution despite not naming Muhammad Faizal out of consideration for his family's need for privacy. Two executions of a 56-year-old man and 45-year-old woman (both convicted of drug offences) were scheduled to take place on 26 July and 28 July 2023 respectively; the female offender Saridewi Djamani was believed to be the first woman to be executed in 19 years, as the last known execution of a woman took place on 19 March 2004, when 37-year-old Yen May Woen was put to death for diamorphine trafficking. The 56-year-old male drug offender Mohd Aziz Hussain, as well as Saridewi, were both hanged as scheduled, becoming the third and fourth persons respectively to be executed in Singapore in the year of 2023. On 3 August 2023, Singapore carried out the hanging of Mohamed Shalleh Abdul Latiff, a 39-year-old Singaporean and former delivery driver found guilty of trafficking 54.04g of diamorphine in 2016. In total, five executions, all once again for drug trafficking, took place in the year 2023. When 35-year-old Ahmed Salim was hanged on 28 February 2024 for murdering his former fiancée, he was the first criminal hanged in Singapore in that year.
Sources: en.wikipedia.org
Despite the independence of strain rate, preconditioned soft tissues still present hysteresis, so the mechanical response can be modeled as hyperelastic with different material constants at loading and unloading. By this method the elasticity theory is used to model an inelastic material. Fung has called this model as pseudoelastic to point out that the material is not truly elastic.
=== Effects of propranolol on other drugs === Propranolol has been found to increase area-under-the-curve levels of propafenone by more than 3-fold. It has been found to increase lidocaine levels by 1.3-fold. The drug has been found to increase peak and area-under-the-curve levels of nifedipine by 1.6-fold and 1.8-fold, respectively. Propranolol decreases theophylline clearance by 30 to 52%. Propranolol inhibits the metabolism of the benzodiazepine diazepam and can increase exposure to diazepam. Conversely, propranolol does not affect various other benzodiazepines, including oxazepam, triazolam, lorazepam, and alprazolam. High-dose long-acting propranolol has been found to increase thioridazine levels by 1.6- to 4.7-fold and levels of its metabolite mesoridazine by 1.3- to 3.1-fold. Propranolol decreased lovastatin or pravastatin area-under-the-curve levels by 18 to 23% but did not affect fluvastatin. It may decrease triiodothyronine (T3) levels when taken with thyroxine (T4). Propranolol has been found to increase the bioavailability and effects of warfarin.
=== Legal status === Tividenofusp alfa was approved for medical use in the United States in March 2026. The US Food and Drug Administration (FDA) granted the application for tividenofusp alfa breakthrough therapy, fast track, priority review, and orphan drug designations. The FDA granted accelerated approval for Avlayah to Denali Therapeutics.
Anna, these actions were "an unparalleled act of violence and unprecedented human rights abuse." It is very certain that this popular unrest was one of the causes for the riots that surrounded the dismissal of Monteagudo on July 25, 1822, since it was perceived, in the feelings of the Lima population of all social classes, as a very unfair act because it is an abuse against Spaniards who had lived in Peru for decades and who had an important social and economic role. According to Scarlett O'Phelan, Monteagudo's measures were about to generate the annihilation of the social group of merchants who were active in very important areas for the Peruvian economy (these being agriculture and, above all, mining). This was due to the fact that the large, small, and medium-sized owners (all expropriated without much difference) were responsible for managing the most vital aspects of the viceroyalty's economy. It is also known that battalions of Argentine origin generated complaints from the civilian population due to the "havoc and exhortations" they carried out on the farms, devastating the crops and even attacking (sometimes seriously injuring) a large part of the members of the Peasant, who worked the land.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.